AstraZeneca's Airsupra cuts risk of severe exacerbations by 47% in patients with milder asthma
AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol, the bronchodilator commonly used for immediate relief from asthma attacks for five decades.
AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol, the bronchodilator commonly used for immediate relief from asthma attacks for five decades.
